Alejandro Pérez Pitarch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alejandro Pérez Pitarch has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Gollner
Boehringer Ingelheim RCV GmbH & Co KG, 1221 Vienna, Austria
41 shared publications - Bojana Golubovic
Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
41 shared publications - Christian Mandl
Oncology Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria, Vienna 1121
41 shared publications - Daniel Gerlach
Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
41 shared publications - Darryl Benjamin McConnell
Boehringer Ingelheim RCV, Vienna, Austria
41 shared publications - Dorothea Rudolph
Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
41 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Modulation of p53 target genes in LU0861 tumor-bearing mice treated with brigimadlin.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Modulation of p53 target genes in LU0861 tumor-bearing mice treated with brigimadlin.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
MDM2 mRNA expression, copy number and brigimadlin in vitro activity in MDM2-amplified cell lines versus MDM2 non-amplified cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
MDM2 mRNA expression, copy number and brigimadlin in vitro activity in MDM2-amplified cell lines versus MDM2 non-amplified cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S9 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Brigimadlin in vitro activity in normal cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Brigimadlin in vitro activity in normal cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
IC50 in mouse cell lines with different TP53 status.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
IC50 in mouse cell lines with different TP53 status.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Brigimadlin dose-dependent regulation of p53 target genes and apoptosis in MDM2-amplified and non-amplified solid tumor cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Brigimadlin dose-dependent regulation of p53 target genes and apoptosis in MDM2-amplified and non-amplified solid tumor cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S11 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Brigimadlin PK parameters in SJSA-1 osteosarcoma MDM2-amplified xenograft model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S11 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Brigimadlin PK parameters in SJSA-1 osteosarcoma MDM2-amplified xenograft model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
TaqMan primer and probe sets used for RT-PCR.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
TaqMan primer and probe sets used for RT-PCR.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
In vitro activity of brigimadlin in normal cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
In vitro activity of brigimadlin in normal cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S13 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Total and unbound brigimadlin in humans and Crl:CD1(ICR) mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S13 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Total and unbound brigimadlin in humans and Crl:CD1(ICR) mice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Antibodies used for Western blot analysis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Antibodies used for Western blot analysis.